NCT03650894View on ClinicalTrials.gov

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 3, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Breast Neoplasm FemaleBreast CancerBreast CarcinomaBreast Tumor
Interventions
DRUG

Nivolumab

Nivolumab 240 mg IV every 2 weeks

DRUG

Ipilimumab

Ipilimumab 1 mg/kg IV every 6 weeks.

DRUG

Bicalutamide

Oral bicalutamide 150mg (3 x 50mg tablets) daily

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

97213

Providence Oncology & Hematology Care Clinic - Eastside, Portland

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Providence Health & Services

OTHER